Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Blood (2023) 142 (Supplement 1): 342.

https://doi.org/10.1182/blood-2023-180006

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Karthik Ramasamy, Niels Abildgaard, Marie-Christiane Vekemans, Barbara Gamberi, Angel Ramírez Payer, Gillian Millar, Annalisa Ansaloni, Margaret Atiba-Davies, David Bernasconi, Torben Plesner, Sujith Dhanasiri

Blood (2022) 140 (Supplement 1): 10000–10001.

https://doi.org/10.1182/blood-2022-162529

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Michel Delforge, Marie-Christiane Vekemans, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Danielle Strens, Sandra Van Hoorenbeeck, Evelien J Moorkens, Joris Diels, Francesca Ghilotti, Sander Dalhuisen, Sophie Vandervennet

Blood (2021) 138 (Supplement 1): 4075.

https://doi.org/10.1182/blood-2021-146250

Published: 2021

Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Blood (2021) 138 (Supplement 1): 80.

https://doi.org/10.1182/blood-2021-152112

Published: 2021

Journal Articles

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira, Inna Y. Gong, Thomas A. Fox, Stephen Booth, Gordon Cook, Bruno Fattizzo, Fernando Martín-Moro, Jerome Razanamahery, John C. Riches, Jeff Zwicker, Rushad Patell, Marie Christiane Vekemans, Lydia Scarfò, Thomas Chatzikonstantinou, Halil Yildiz, Raphaël Lattenist, Ioannis Mantzaris, William A. Wood, Lisa K. Hicks

Blood (2020) 136 (25): 2881–2892.

https://doi.org/10.1182/blood.2020008824

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients

Abi Vijenthira, MD, Inna Gong, MD, Thomas A Fox, BSc, MSc, MRCP, Stephen Booth, Gordon Cook, MB ChB, PhD, Bruno Fattizzo, MD, Fernando Martín Moro, Jerome Razanamahery, MD, John Riches, MD PhD, Jeffrey I. Zwicker, MD, Rushad Patell, MBBS, Marie Christiane Vekemans, Lydia Scarfo, Thomas Chatzikonstantinou, Halil Yildiz, MD, Raphael Lattenist, MD, Ioannis Mantzaris, MD MS, William Wood, MD, Lisa K. Hicks, MD MSc

Blood (2020) 136 (Supplement 1): 39–41.

https://doi.org/10.1182/blood-2020-141235

Published: 2020

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Niels Abildgaard, MD PhD, Marie-Christiane Vekemans, Barbara Gamberi, MD, Francesco Di Raimondo, MD, Angel Ramirez Payer, Charalampia Kyriakou, Alain Kentos, Elisabeth Kueenburg, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Margaret Atiba-Davies, Torben Plesner, MD DSc

Blood (2018) 132 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2018-99-111906

Published: 2018

Journal Articles

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Francesco Di Raimondo, Charalampia Kyriakou, Martin Schmidt-Hieber, Marie-Christiane Vekemans, Ángel Ramírez Payer, Pal Tore Bentsen, Birgitta Lauri, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Torben Plesner, Professor

Blood (2016) 128 (22): 5680.

https://doi.org/10.1182/blood.V128.22.5680.5680

Published: 2016

Journal Articles

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Blood (2016) 128 (22): 3467.

https://doi.org/10.1182/blood.V128.22.3467.3467

Published: 2016

Journal Articles

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Thomas Pabst, Edo Vellenga, Wim van Putten, Harry C. Schouten, Carlos Graux, Marie-Christiane Vekemans, Bart Biemond, Peter Sonneveld, Jakob Passweg, Leo Verdonck, Marie-Cecile Legdeur, Matthias Theobald, Emanuel Jacky, Mario Bargetzi, Johan Maertens, Gert Jan Ossenkoppele, Bob Löwenberg

Blood (2012) 119 (23): 5367–5373.

https://doi.org/10.1182/blood-2011-11-389841

Published: 2012

Includes: Supplemental data

Journal Articles

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

Blood (2010) 116 (21): 3043.

https://doi.org/10.1182/blood.V116.21.3043.3043

Published: 2010

Journal Articles

The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome

Marie-Christiane Vekemans, Heidi Lemmens, Chantal Doyen, Greet Bries, HIlde Demuynck, Pascal Pierre, Jan Lemmens, Peter Meeus, Michel Delforge, Deborah Bauwens, Iwona Wlodarska, Peter Vandenberghe, Lucienne Michaux

Blood (2008) 112 (11): 2718.

https://doi.org/10.1182/blood.V112.11.2718.2718

Published: 2008

NARROW

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only